ANTIBODY RESPONSES OF RED WOLVES TO CANINE DISTEMPER VIRUS AND CANINE PARVOVIRUS VACCINATION

Lisa A. Harrenstien,1 Linda Munson,1 Edward C. Ramsay,2 Christopher F. Lucash,3 Stephen A. Kania,2 and Leon N. D. Potgieter2

1 Department of Pathology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee 37901, USA
2 Department of Comparative Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee 37901, USA
3 Red Wolf Recovery Program, U.S. Fish and Wildlife Service, Townsend, Tennessee 37882, USA

ABSTRACT: Twenty captive red wolves (Canis rufus), including 16 intended for release into Great Smoky Mountains National Park, Cades Cove, Tennessee (USA), and four housed at Knoxville Zoological Gardens, Inc., Knoxville, Tennessee, were evaluated for immunologic response to vaccination between June 1994 and April 1995. Wolves were vaccinated with modified-live (MLV) canine distemper virus (CDV) and canine parvovirus type-2 (CPV2). Sera were collected, and immunofluorescent staining was performed for determination of immunoglobulin titers (CDV IgM, CDV IgG, and CPV2 IgG). A capture enzyme-linked immunosorbent assay was performed for validation purposes, to confirm the reactivity of our standard diagnostic reagents with red wolf serum. All wolves produced a measurable antibody response to CDV and CPV2 vaccination. Titers against CDV and CPV2 varied widely among individual wolves, but between-litter differences in mean titers were not significant. No consistent response between the degree of response to CDV versus CPV2 vaccination was observed in individual wolves. No differences were seen between IgG responses of pups vaccinated with univalent vaccines given concurrently or during alternating weeks. Pups had an IgG response to CDV and CPV2 vaccination as early as 9 wk of age. Mean post-vaccination IgG titers against CDV were at or above the level normally measured in vaccinated domestic dogs. Mean post-vaccination IgG titers against CPV2 were below the level normally measured in domestic dogs. Adult previously-vaccinated wolves had measurable CDV and CPV2 IgG titers more than 1 yr after vaccination, but did not have significant IgG titer increases after revaccination. We conclude that red wolves are capable of producing an antibody response after vaccination with commercial canine products but that their response to CPV2 vaccination was minimal. This response can be assayed using tests developed for domestic dogs.

Key words: Red wolf, Canis rufus, vaccination, canine distemper virus, canine parvovirus, serology.

INTRODUCTION

Canine distemper virus (CDV) and canine parvovirus type-2 (CPV2) have caused disease and death in many species of canids (Montali et al., 1987a, b, J. Zuba, pers. comm.). Based on serologic and virus isolation studies, CDV and CPV2 have been implicated in population decreases of several wild canid species (Alexander and Appel, 1994; Alexander et al., 1994; Johnson et al., 1994). Protection of non-domestic carnivores by vaccination against these viruses has been problematic, however, due to variable serologic responses to vaccines, unknown duration of maternal immunity in neonates, and vaccine-induced disease associated with use of modified-live-virus (MLV) CDV products of canine cell line origin (Montali et al., 1983). Furthermore, controversy exists whether transient immunosuppression may result from use of multivalent MLV vaccine products (Greene, 1990).

Two free-ranging juvenile red wolves (Canis rufus) of the Red Wolf Recovery Program of the U.S. Fish and Wildlife Service (USFWS), Great Smoky Mountains National Park (GSMNP), Cades Cove, Tennessee (USA) (35°37’N, 83°48’W) were found dead in July 1993. Canine parvovirus type-2 was isolated from the intestinal tract of one of the wolves and was suspected as the cause of death, although autolysis precluded definitive diagnosis (N. Thomas, pers. comm.). The mother of these pups had been vaccinated 10 mo previously with a multivalent MLV vaccine, yet her CPV2 immunoglobulin (IgG)
This study was conducted between June 1984 and April 1985. Twenty captive red wolves from the USFWS, including 16 housed at GSMNP, were included. Males were housed in chain-link enclosures in family groups of 2 to 4 yr at the start of the study. Wolves were housed at least 6 wk in outdoor chain-link enclosures approximately 235 m² in area, and were fed dry dog food (Diamond Pet Foods, Meta, Missouri, USA), deer (Odocoileus horridus) carcasses, and water ad libitum. 

Table 1. Animal groups and regimen for vaccination and serum collection for red wolf study.

<table>
<thead>
<tr>
<th>Group description</th>
<th>Sample size</th>
<th>Age at beginning of study</th>
<th>Time elapsed since previous vaccination</th>
<th>Vaccination regimen (age)</th>
<th>Serum collection regimen (age)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Pups vaccinated concurrently with univalent vaccines</td>
<td>5</td>
<td>6 wk</td>
<td>NA</td>
<td>CDV³ and CPV² at both 6 and 9 wk</td>
<td>6, 9, and 52 wk</td>
</tr>
<tr>
<td>B. Pups vaccinated in alternating weeks with univalent vaccines</td>
<td>8</td>
<td>6 wk</td>
<td>NA</td>
<td>CDV at 6, 9, 12, 15, and 18 wk; CPV² at 7, 10, 13, 16, and 19 wk</td>
<td>6, 9, 12, 15, 18 and 21 wk</td>
</tr>
<tr>
<td>C. Adults vaccinated as pups³</td>
<td>5</td>
<td>17 or 20 mo</td>
<td>14 or 17 mo</td>
<td>CDV and CPV² at 6, 12, and 15 wk</td>
<td>17 or 20 mo</td>
</tr>
<tr>
<td>D. Adults following booster vaccination</td>
<td>3</td>
<td>2, 4, or 5 yr</td>
<td>2, 8, or 21 mo</td>
<td>CDV and CPV² at 2, 4, and 5 yr</td>
<td>Prior to and 3 wk after booster vaccination</td>
</tr>
</tbody>
</table>

* NA = not applicable.  
³ CDV = Fromm D³ modified live canine distemper vaccine (Solvay Animal Health, Inc.), 1 ml administered subcutaneously.  
³ CPV² = Duramune² KP-11 canine parvovirus type-2 vaccine (Fort Dodge Laboratories), 1 ml administered subcutaneously.  
³ Group A pups were released from captivity at age 9 wk, visually monitored periodically, and placed back into captivity at age 8 mo.  
³ Duramune² DA²P²PV² Leptospirosis vaccine (Fort Dodge Laboratories), 1 ml administered subcutaneously or intramuscularly.
tered subcutaneously), and blood samples were collected via jugular, cephalic, or saphenous veins, using manual restraint, as described in Table 1. The adult wolves (Groups C and D) had been previously vaccinated with Duramune® DA2F + PV + Leptospira canicolaicterohaemorrhagiae (Fort Dodge Laboratories, Inc., 1 ml administered subcutaneously or intramuscularly). Clotted blood samples were centrifuged, and the sera separated and frozen within 4 hr after blood collection. Sera were stored at −70 C until serology could be performed.

To assess the reactivity of our diagnostic reagents with non-domestic canid serum, a capture enzyme-linked immunosorbent assay (ELISA) was performed; we compared immunoglobulin binding patterns of domestic dog IgG and red wolf serum. Domestic cat IgG and bovine IgG were also analyzed by this ELISA for comparison of binding among unrelated species. The capture ELISA procedure was: Immulon 2 ELISA plates (Dynatech Laboratories, Inc., Chantilly, Virginia, USA) were coated with 5 µg/ml of affinity-isolated rabbit anti-dog IgG (Sigma Chemical Company, St. Louis, Missouri), incubated 16 to 24 hr at 0C, then washed with phosphate buffered saline (PBS) containing 0.05% Tween 20 (PBSTW) and blocked for 30 min with PBSTW. Samples to be tested included dog serum, red wolf serum, purified canine IgG, purified feline IgG, and purified bovine IgG. Sera were diluted (1: 20,000 to 1:5,500,000) in PBSTW, and 100 µl of each sample were dispensed into each plate well. Samples were incubated at 37 C for 1 hr, then washed with PBSTW. Phosphatase-conjugated, affinity-isolated, rabbit anti-dog IgG was diluted 1:2000 in PBSTW and 100 µl was added to each plate well, then samples were again incubated at 37 C for 1 hr, washed with PBSTW, and washed with PBS. 100 µl of phosphatase substrate (Sigma) was then added to each well, and the optical density of each sample was determined at 405 nm.

Each wolf serum sample was assayed for CDV IgM, CDV IgG, and CPV2 IgG, using domestic canine reagents and the immunofluorescent staining (IFA) techniques of Rovozzo and Burke (1973), with the following modifications. Antigen slides for CDV and CPV2 were prepared using Vero (for CDV) (American Type Culture Collection, Rockville, Maryland, USA) or feline kidney cells (for CPV2) (American Type Culture Collection), cultured in Dulbecco's Modified Eagles Medium plus 10% fetal bovine serum. Kidney cells were inoculated with virus, harvested, rinsed and resuspended with PBS, and 5 µl were added to glass microscope slides. Approximately 70% of cells in CDV slide aliquots were infected with CDV, and approximately 40% of cells in CPV2 slide aliquots were infected with CPV2. Serum doubling dilutions of 1:10 to 1:40 were used for CDV IgM titer measurement, dilutions of 1:20 to 1:640 were used for CDV IgG titer measurement, and dilutions of 1:5 to 1:640 were used for CPV2 IgG titer measurement. Fluorescent anti-dog antibody conjugates were diluted 1:200 (anti-dog IgM, Organon-Teknika Corporation, Durham, North Carolina, USA) or 1:150 (anti-dog IgG, Miles Laboratories, Kankakee, Illinois, USA) and applied to antigen-antibody sample areas. Dried slides were then examined for significant cell fluorescence using a darkfield microscope. A serum antibody titer was considered to be the highest dilution that had faint fluorescence. Purified antibody (Sigma) and canine sera of known titers (Clinical Virology Laboratory, University of Tennessee College of Veterinary Medicine, Knoxville, Tennessee) were assayed along with all test runs, to serve as positive controls. To minimize the effects of variation between test runs, all sera from an individual wolf were assayed in the same test run. Assays were performed without knowledge of sample identity.

Mean titers and standard errors were calculated geometrically and compared using the two-tailed Student's t test, at a significance level of P < 0.05 (Strike, 1991). Titers of ≥1:640 were assigned values of 1:640, CDV IgM titers of <1:10 were assigned values of one, CDV IgG titers of <1:20 were assigned values of one, and CPV2 IgG titers of <1:5 were assigned values of one for use in calculation of mean titers.

RESULTS

Based on the capture ELISA, anti-dog IgG reacted approximately 80% as strongly to a randomly-selected serum sample from a healthy adult red wolf as it did to a randomly-selected serum sample from a healthy adult domestic dog (Fig. 1). The difference between canine versus wolf serum reactivity for each serum dilution was significantly less than the intraspecies difference between stepwise dilutions (P < 0.05).

Canine distemper virus IgM titers were ≥1:10 in all sera tested, except in one 6 wk old pup (1:20).

At age 51 wk, CPV2 IgG titers persisted in the three wolves of Group A that could be tested (Fig. 2). Wide variation was noted in both CDV and CPV2 IgG titers
among individual animals in Group B (Fig. 3).

Canine distemper virus IgG titers ranged from 1:160 to 1:640 (mean \( \pm \) SE = 1:416 \( \pm \) 96) and CPV2 IgG titers ranged from 1:10 to 1:80 (mean \( \pm \) SE = 1:34 \( \pm \) 14) in wolves of Group C.

Group D consisted of adult wolves revaccinated as adults. Pre-booster CDV IgG titers ranged from 1:40 to 1:160 (mean \( \pm \) SE = 1:93 \( \pm \) 35), and CPV2 IgG titers ranged from 1:40 to 1:80 (mean \( \pm \) SE = 1:53 \( \pm \) 13). These adult females’ most recent vaccinations had been administered 8 to 23 mo previously, using a multivalent vaccine. Three weeks after re-inoculation with univalent vaccines, their CDV IgG titers ranged from 1:80 to 320 (mean \( \pm \) SE = 1:160 \( \pm \) 80), and CPV2 IgG titers ranged from 1:20 to 1:80 (mean \( \pm \) SE = 1:46 \( \pm \) 17).

DISCUSSION

In this study we demonstrated that red wolves are capable of producing an antibody response after vaccination with commercial canine products, and that this response can be assayed using tests developed for domestic dogs. The small observed disparity between wolf and domestic canine serum reactivities is within the expected range of accuracy of immunofluorescent antibody tests and is well within the variation range which would be expected between sera of different individual conspecific animals (Pedersen, 1995).

The red wolf pups of Groups A and B of this study generated significant IgG responses after their first CDV vaccination at age 6 wk. Further IgG titer increases were noted after the second CDV vaccination (age 9 wk), and subsequent CDV IgG titers remained at this level beyond age 21 wk. These observations agree with Greene (1990) regarding vaccine efficacy and scheduling in domestic dog pups.
The pups' first (age 6 wk) vaccination against CPV2 also stimulated IgG titer increases, although they were of less magnitude than for CDV. Subsequent CPV2 IgG titers remained at this level through 21 wk of age. These data are in contrast to observations of domestic dog pups, in which CPV2 vaccines may not stimulate IgG titer increases until 12 to 20 wk of age (Greene, 1990), as well as maned wolf pups (*Chrysocyon brachyurus*) (earliest CPV2 vaccination response at 14 to 18 wk of age) and bush dog pups (*Speothos venaticus*) (earliest CPV2 vaccination response at 23 wk of age) (Janssen et al., 1982). Early CPV2 IgG response in the red wolf pups of this study may be due to lack of interference from maternally-derived passive immunity, although the mothers' mean CPV2 IgG titer was similar to the mean titer of other adult red wolves. Alternatively, it may be due to a possible difference in the immunogenicity and pathogenicity of CPV2 in red wolves compared to other canids.

Genetic background did not consistently determine antibody response. Titers varied widely among individual wolves, but between-litter differences in mean titers were not statistically significant. No consistent relationship could be detected between degree of response to CDV versus CPV2 vaccination in individual wolves.

No definite conclusions can be made regarding the possibility of multivalent, concurrent univalent, or alternate-week univalent vaccine-induced immunosuppression in red wolf pups. Examining pre-vaccination (age 6 wk) and post-vaccination (age 9 wk) data, there were no differences in pups' IgG responses to univalent vaccines given concurrently (Group A) or during alternate weeks (Group B); thus both vaccination regimens probably have similar immunomodulating effects. Two of five pups given concurrent vaccinations could not be found for recapture at the end of the free-ranging period post-vaccination, and were presumed dead. Vaccine-induced disease cannot be ruled out as their cause of death, although their mortality rate is well within that expected for free-ranging pups that have not been vaccinated (C. Lucash, unpub.), and vaccine-induced disease has never been identified in captive red wolves. Further studies are needed to determine the effects of concurrent CDV/CPV2 vaccination on immune function in red wolves.

Adult red wolves' IgG titers for both CDV and CPV2, measured 17 to 20 mo after their juvenile multivalent vaccine series, were similar to the longterm post-vaccination data from other red wolves of this study. Although these adults' titers as juveniles were not known, we conclude that measurable IgG titers are present in red wolves more than 1 yr after juvenile vaccination for CDV and CPV2. Exposure to wild type virus due to contact with wild and feral mammals cannot be excluded as a possible additional stimulus for antibody production, although recent (≤90 days previous) exposure to virulent virus would have also been evidenced by increased IgM titers (Appel, 1987).

Adult red wolves revaccinated with univalent vaccines had no significant changes in IgG titers for either CDV or CPV2. Thus, their immune responses probably had reached maximum levels before the repeat vaccination was performed. Alternatively, adult wolves could take longer than 3 wk to respond measurably to revaccination, as has been suggested by Spencer and Burroughs (1990) for the vaccine responses of wild dogs (*Lycaon pictus*).

It is not yet possible to define the protective benefit of the CDV and CPV2 IgG titers measured in this study. For domestic dog sera evaluated by IFA at the University of Tennessee College of Veterinary Medicine Clinical Virology Laboratory, a CDV or CPV2 IgG titer of ≥1:160 was considered to be substantial, and may correlate with protection (M. Kennedy, pers. comm.). The titers measured in this study should not be presumed to afford protection of red wolves from viral challenge, however. Further studies are needed to as-
assess the protection afforded to red wolves by CDV and CPV2 vaccination.

ACKNOWLEDGMENTS

The authors greatly appreciate the assistance of Barron Crawford, John Weller, Dr. Melissa Kennedy, and Kent Millsaps. We also thank the Red Wolf Species Survival Plan (Will Waddell, Coordinator) and the American Zoo and Aquarium Association for their support of this research.

LITERATURE CITED


Received for publication 24 July 1995.